Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human immunodeficiency virus (HIV) infection. The mean minimal plasma APV concentrations in groups A and B were 58 and 1,320 ng/ml, respectively, corresponding to APV inhibitory quotients of 0.2 (range, 0.03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses.
Duval
Xavier
X
Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, Paris, France. xavier.duval@bch.ap-hop-paris.fr
Lamotte
Claire
C
Race
Ester
E
Descamps
Diane
D
Damond
Florence
F
Clavel
François
F
Leport
Catherine
C
Peytavin
Gilles
G
Vilde
Jean-Louis
JL
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates; D004359:Drug Therapy, Combination; D005663:Furans; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D012367:RNA, Viral / Q000187:drug effects*; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D012367:RNA, Viral; D013449:Sulfonamides; C095108:amprenavir; D019438:Ritonavir